skip to Main Content
UK Government Looks To Remove Hemp and Cannabinoids From Home Office Oversight To Boost Industry’s Growth

GOOD news for UK hemp and cannabis today with the unveiling of proposals which could free the industry from the regulatory grip of the crime-focused Home Office and unleash its economic and well-being potential.

BusinessCann reported in April how senior advisors to Boris Johnson were suggesting new rules for hemp cultivation and cannabinoid research.

And, today the 130-page Final Report by The Taskforce on Innovation, Growth and Regulatory Reform (TIGRR) recommends a significant overhaul of the current system.

Report authors ex-Tory leader Sir Iain Duncan-Smith and MPs George Freeman and Theresa Villiers highlight two problems with the existing hemp and cannabinoid licensing rules.

Rules Based On Patient Benefit

And go on to say in a recommendation summary that: ‘Regulation of medical cannabinoids and medicinal CBD should move from the Home Office to the DHSC / MHRA (Department of Health and Social Care and Medicines and Healthcare products Regulatory Agency) to create a regulatory pathway for assessment and approval based on patient benefit.’

“Grow Our Own”

Siân Phillips, Managing Director, of the Cannabis Trades Association, welcomed the moves to free-up hemp cultivation – which should remove the restrictions on the use of flowers and leaves – but expressed concerns over its failure to recognise the sustainable benefits of the hemp plant and how the process will impact over-the-counter CBD and vaping industries.

Jamie Bartley, CEO, of Unyte Hemp and a member of the recently-formed UK Cannabis Industry Council welcomed the suggestions.

He went on to say: “We need to remove cannabis from the Misuse of Drugs Act in its entirety, there is no evidence of harm and there is lots of evidence of its medical benefit.

“Without a streamlining of the licensing framework, we will not see any significant growth in the sector. We need a cannabis department within government that has representation from all stakeholder departments and engages with industry – we need a collaborative approach.”

The TIGRR report highlights two issues with UK hemp and cannabinoid licensing saying: The first is the current regime makes it very difficult for scientists in the UK to conduct pharmaceutical research on potential medical benefits of cannabinoids and medicinal CBD. 

International examples and leading scientists working in this area have shown that sensible, but limited, reforms to the current licensing process could unlock significant investment into UK medical research into cannabinoids for pain relief’. 

The report then goes on to say:  The second is the dichotomy that whilst there is in the UK a fast-growing, legal and well established consumer market for medicinal CBD for a range of pain and neurological conditions, current Home Office rules make it impossible for them to be produced here. This means that domestic consumers are relying on imported products and the UK is losing out on a c£1 billion medicines industry.

Separate From Criminal Law

And adds: ‘At present this is prevented because the rules governing CBD medicines are not properly separated from the criminal law on banned substances derived from cannabis.

Our recommendations cover legal-to-use CBD medicinal products only. This report has focused on potential medical usage and does not recommend decriminalisation for recreational use.’ 

TIGRR was launched to examine how the UK can boost its economy by taking advantage of its post-Brexit regulatory freedoms.

It also examines the role sectors such as financial services, energy, transport, agriculture and ‘Net-Zero’ technologies, such as offshore wind and hydrogen can play in supporting UK growth.

Prime Minister Boris Johnson welcomed the report today saying: “Your report shows what a fully sovereign United Kingdom can achieve given sufficient ambition and vision on the part of its government. I look forward to drawing on your work in the months and years ahead as we build back better than ever before.”

A spokesman for the Prime Minister’s office says it will consider and respond to the report’s recommendations in due course.

Click here to read the full TIGRR report.

Peter McCusker

Peter McCusker

Peter McCusker is the Founder and Editor of BusinessCann and an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant. BusinessCann covers the ins and outs of the growing European Regulated Medical Marijuana marketplace. Peter can be reached at [email protected].

BusinessCann is an online news publication, which supports the growth of Europe’s Hemp, CBD and Medicinal Cannabis industries by providing factual and feature articles, comment and profiles on the people and businesses forging its growth and development.
This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Stories

Dug In: Big Island Grown’s Deep Cannabis Roots

Big Island Grown (BIG) is a vertically integrated cannabis company based in Kailua-Kona, Hawaii County, on the Big Island of Hawaii, whose reach now extends to several islands in the…

Unlock the Secrets of Social Media for Cannabis Brands

There are three primary ways that brands can use social media platforms for marketing: organic posts, shared posts, and paid posts. With paid posts still off limits to most businesses…

California’s Cannabis Industry Conundrum and the Road Ahead

By Aaron Pelley, Attorney at Harris Sliwoski Despite continuously surpassing every other state with recreational cannabis in terms of total retail sales, California’s cannabis industry has faced continuous and far-reaching…

The High Rate of Dependence Among Medical Cannabis Users

The difference between medicinal and recreational marijuana has always been arbitrary. For example, after legalizing recreational cannabis, California initially required each cultivated seedling to be designated by growers as either…

More Categories

Back To Top
×Close search
Search